Indeed, we observed significantly less numbers of FasL+CD31+ tumor endothelial cells in Groups B and C when compared to Group A (vs. Group B: P = 0.031; vs. Group C: P = 0.008) and PBS-treatment (vs. Group B: P = 0.006; vs. Group C: P = 0.002) (Fig. 4C, left panel). The gene discussed is FASLG; the disease is neoplasm.